Spots Global Cancer Trial Database for A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
Official Title: A Phase 1, Multicenter, Dose-Escalation Study to Investigate the Safety and Tolerability of ADH-1 in Combination With 1) Carboplatin or 2) Docetaxel or 3) Capecitabine in Subjects With N-Cadherin Positive, Advanced Solid Tumors (Adherex Protocol Number AHX-01-006)
Study ID: NCT00390676
Conditions
Study Description
Brief Summary: N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Rocky Mountain Cancer Centers, Denver, Colorado, United States
Cancer Centers of Florida, Ocoee, Florida, United States
Central Indiana Cancer Centers, Indianapolis, Indiana, United States
New York Oncology Hematology P.C., Albany, New York, United States
Dayton Oncology & Hematology, P.A, Kettering, Ohio, United States
Cancer Centers of the Carolinas, Greenville, South Carolina, United States
Texas Oncology, PA, Dallas, Texas, United States
Tyler Cancer Center, Tyler, Texas, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Northwest Cancer Specialists - Vancouver Cancer Center, Vancouver, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
